

Site-specific Assessment (SSA) Checklist

The following checklist/guidance information is provided to assist with your SSA application; it is not required for submission. **Please note:** For applications submitted via the Mater Priority Trials Review service, refer to separate checklist.

All clinical research projects	
Signed SSA form	
- The submitted SSA form must include the following prior to submission in ERM: a. Principal Investigator for Mater	
b. Head/s of Department/s	
c. Medical Director/s or Chief Medical Officer/s	
d. General Manager/s	
- For funded projects only:	
c. Management Accountant	
If the Mater Misericordiae Ltd HREC is the approving HREC, you do not need to upload HREC approvals or approved documents in the SSA. RGO only require additional site-specific documents (e.g. site-specific PICFs, site level approvals/letters of support, budget, quotes).	
HREC approval letter/s	
- The Mater site should be listed as Mater Misericordiae Ltd	
- All approval letters should be included (initial approval and any subsequent amendment approvals)	
- If a waiver of consent is approved, Mater requires evidence that s95A of the Privacy Act was considered	
Protocol	
Master PICF (for multi-site projects)	
Mater site PICF	
- Footer details - the site version and date. For multisite projects, include the version and date of the Master PICF on which it is based, e.g. Mater PICF Version 1 dated 20 Feb 2024; based on Master PICF Version 1 dated 11 Jan 2024	
- Where relevant, include the Mater Research logo on the front page	
- Mater institution should be referred to as Mater Misericordiae Limited and/or the correct Mater hospital/location name/s	
- For projects approved by an external HREC, include contact details for Mater RGO - Research Governance Officer, Ph: 07 3163	
3769, Email: <u>research.governance@mater.uq.edu.au</u>	
- For multi-site projects, site-specific PICFs must be tracked from the Master PICFs and a tracked and clean version provided	
All HREC approved documents	
All current documents: documents that have been superseded prior to SSA submission do not need to be submitted.	
Budget	
Actual funding and in-kind support must be detailed, either within the SSA form or as an attached document.	
Other – submit if applicable to your project	
CTN	
- If externally sponsored, provide the draft/submitted CTN including Mater approving authority details. The TGA-acknowledged CTN	
will be required prior to authorisation.	
- If Mater sponsored, Mater RGO will submit the CTN to TGA, in consultation with the research team.	
Early Phase Clinical Trials Risk Assessment endorsement letter	
Phase 1 and 2a clinical trials: A separate 'Mater Early Phase Clinical Trial Risk Assessment' application must be submitted in ERM. The	
SSA review can commence prior to endorsement but cannot be authorised until this is received.	
Drug/Device Information/ Investigator's Brochure	
Quotes and/or Service Agreements	
Including internal services (e.g. Mater Pharmacy, Mater Pathology) and external service providers	
Radiation Safety Report	
Biosafety approval and OGTR approval	
QCAT approval letter	

For queries, please contact the Mater Research Governance Office - Email: research.governance@mater.uq.edu.au